OrbiMed Advisors and Lilly Asia Ventures are two important investors in ADARx Pharmaceuticals $75 million series B financing, putting money into RNA-targeting technologies. According to…
OrbiMed Advisors and Lilly Asia Ventures are two important investors in ADARx Pharmaceuticals $75 million series B financing, putting money into RNA-targeting technologies. According to…